E-Mail 'Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)' To A Friend
Email a copy of 'Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)' to a friend
Loading ...Gastroenterology training and education
Largest online gastroenterology, hepatology and endoscopy education and training resource with histology, x-ray images, videos, gastro calculators, and MCQs.
Loading ...Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)
BOSTON (MedPage Today) — For patients with chronic hepatitis B, long-term treatment with entecavir (Baraclude) significantly cut the risk of liver cancer, researchers reported.
Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)
BOSTON (MedPage Today) — For patients with chronic hepatitis B, long-term treatment with entecavir (Baraclude) significantly cut the risk of liver cancer, researchers reported.
Antiviral Drug Cuts Cancer Risk in Hepatitis B (CME/CE)
BOSTON (MedPage Today) — For patients with chronic hepatitis B, long-term treatment with entecavir (Baraclude) significantly cut the risk of liver cancer, researchers reported.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information:
verify here.